IN2012DN00928A - - Google Patents
Info
- Publication number
- IN2012DN00928A IN2012DN00928A IN928DEN2012A IN2012DN00928A IN 2012DN00928 A IN2012DN00928 A IN 2012DN00928A IN 928DEN2012 A IN928DEN2012 A IN 928DEN2012A IN 2012DN00928 A IN2012DN00928 A IN 2012DN00928A
- Authority
- IN
- India
- Prior art keywords
- treatment
- relates
- benzylideneaminoguanidines
- dimethoxybenzylideneamino
- guanidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the use of benzylideneaminoguanidines for the treatment of inflammation and pain. In one preferred embodiment, the invention relates to the use of N-(2-chloro-3,4-dimethoxybenzylideneamino)guanidine for the treatment of rheumatoid arthritis.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0913427A GB0913427D0 (en) | 2009-07-31 | 2009-07-31 | Compounds for treatment of imflammation |
GBGB1005495.5A GB201005495D0 (en) | 2010-03-31 | 2010-03-31 | Compounds for treatment of inflammation |
GBGB1010671.4A GB201010671D0 (en) | 2010-06-24 | 2010-06-24 | Compounds for treatment of inflammation |
PCT/GB2010/001457 WO2011012868A1 (en) | 2009-07-31 | 2010-07-30 | Compounds for treatment of inflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN00928A true IN2012DN00928A (en) | 2015-04-03 |
Family
ID=42799430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN928DEN2012 IN2012DN00928A (en) | 2009-07-31 | 2010-07-30 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20120190751A1 (en) |
EP (1) | EP2470270A1 (en) |
JP (1) | JP2013500957A (en) |
CN (1) | CN102573993A (en) |
AU (1) | AU2010277356A1 (en) |
BR (1) | BR112012002267A2 (en) |
CA (1) | CA2769541A1 (en) |
GB (1) | GB2473095A (en) |
IN (1) | IN2012DN00928A (en) |
MX (1) | MX2012001144A (en) |
NZ (1) | NZ598124A (en) |
RU (1) | RU2012106467A (en) |
WO (1) | WO2011012868A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3109237A1 (en) * | 2015-06-22 | 2016-12-28 | AnaMar AB | Novel 5-ht2 antagonists |
CN105561313B (en) * | 2016-01-25 | 2018-12-25 | 北京大学 | It reduces 5-HT2BR content and its active substance is inhibited to treat and prevent the application in atherosclerosis product in preparation |
US11208475B1 (en) * | 2018-01-30 | 2021-12-28 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators |
JP2021529729A (en) * | 2018-05-09 | 2021-11-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Use of guanabenz or its derivatives to treat type I IFN-dependent pathology |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE171067T1 (en) * | 1990-03-16 | 1998-10-15 | Beth Israel Hospital | USE OF SPIPERONE AS AN IMMUNOSUPRESSANT AND ANTI-INFLAMMATORY AGENT |
US5696128A (en) * | 1994-07-07 | 1997-12-09 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method of regulating immune function |
EP0711553A1 (en) * | 1994-08-09 | 1996-05-15 | Mario Cagnoni | Use of the Melatonin in the traetment of the articular symptoms of trheumatoid arthritis |
WO2001025192A1 (en) * | 1999-10-06 | 2001-04-12 | Melacure Therapeutics Ab | Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase |
GB0019357D0 (en) * | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
US7060711B2 (en) * | 2001-10-25 | 2006-06-13 | Biofrontera Bioscience Gmbh | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist |
EP1687641A2 (en) * | 2003-09-25 | 2006-08-09 | Acadia Pharmaceuticals Inc. | Treating neuropathic pain with neuropeptide ff receptor 2 agonists |
GB0623381D0 (en) * | 2006-11-23 | 2007-01-03 | Acure Pharma Ab | Use of a compound as VEGF inhibitor |
GB0701170D0 (en) * | 2007-01-22 | 2007-02-28 | Imp Innovations Ltd | Compositions and uses thereof |
GB0715048D0 (en) * | 2007-08-02 | 2007-09-12 | Glaxo Group Ltd | Novel compounds |
EP2411812B1 (en) * | 2009-03-24 | 2013-10-02 | AnaMar AB | Metabolic profiles |
-
2010
- 2010-07-30 BR BR112012002267A patent/BR112012002267A2/en not_active IP Right Cessation
- 2010-07-30 US US13/388,174 patent/US20120190751A1/en not_active Abandoned
- 2010-07-30 AU AU2010277356A patent/AU2010277356A1/en not_active Abandoned
- 2010-07-30 MX MX2012001144A patent/MX2012001144A/en unknown
- 2010-07-30 EP EP10739974A patent/EP2470270A1/en not_active Withdrawn
- 2010-07-30 JP JP2012522246A patent/JP2013500957A/en active Pending
- 2010-07-30 RU RU2012106467/15A patent/RU2012106467A/en not_active Application Discontinuation
- 2010-07-30 IN IN928DEN2012 patent/IN2012DN00928A/en unknown
- 2010-07-30 GB GB1012926A patent/GB2473095A/en not_active Withdrawn
- 2010-07-30 CA CA2769541A patent/CA2769541A1/en not_active Abandoned
- 2010-07-30 NZ NZ598124A patent/NZ598124A/en unknown
- 2010-07-30 CN CN2010800325573A patent/CN102573993A/en active Pending
- 2010-07-30 WO PCT/GB2010/001457 patent/WO2011012868A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP2013500957A (en) | 2013-01-10 |
GB201012926D0 (en) | 2010-09-15 |
GB2473095A (en) | 2011-03-02 |
EP2470270A1 (en) | 2012-07-04 |
RU2012106467A (en) | 2013-09-10 |
WO2011012868A1 (en) | 2011-02-03 |
US20120190751A1 (en) | 2012-07-26 |
BR112012002267A2 (en) | 2016-11-08 |
AU2010277356A1 (en) | 2012-03-08 |
MX2012001144A (en) | 2012-05-08 |
NZ598124A (en) | 2014-01-31 |
CN102573993A (en) | 2012-07-11 |
CA2769541A1 (en) | 2011-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014011134A (en) | Carbamate compounds and of making and using same. | |
EA201491617A1 (en) | CONNECTIONS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | |
MX2009009079A (en) | Engineered anti-il-23p19 antibodies. | |
MX2009009080A (en) | Engineered anti-il-23p19 antibodies. | |
PH12014501736B1 (en) | Therapeutic use of p75ntr neurotrophin binding protein | |
MX2011007930A (en) | Crystalline insulin-conjugates. | |
TN2012000302A1 (en) | Oxyntomodulin peptide analogue | |
MX2009009283A (en) | Engineered anti-il-23r antibodies. | |
MY184241A (en) | Human antibodies to gfr?3 and methods of use thereof | |
MX2009011346A (en) | Tapentadol for treating pain from arthritis. | |
MY143269A (en) | Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder | |
MY155340A (en) | Use of cathepsin c | |
IN2012DN00928A (en) | ||
TR200909786A1 (en) | Effervescent tablet and granule formulation containing cefixime. | |
HK1141436A1 (en) | Axomadol for treating pain from arthritis | |
HUE047515T2 (en) | N-substituted benzenepropanamides for use in the treatment of pain and inflammation | |
IL223065A0 (en) | New cathepsin s protease inhibitors, useful in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions | |
SG178929A1 (en) | Use of cathepsin h | |
LV14346A (en) | 4r,5s-enantiomer of 2-(5-methil-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity | |
UA44395U (en) | Use of tiocetam as a diuretic drug with mild emictory action in a complex treatment | |
UA110918C2 (en) | Inhibitors of protein phosphatase-1 and their use | |
UA45304U (en) | Method for assessment of the patient state with rheumatoid arthritis and efficiency of its treatment | |
UA50825U (en) | Use of antagonist of interleukin-1 receptor as hypouricemic agent | |
UA52805U (en) | Nasal splint | |
UA106224C2 (en) | Crystalline insulin-conjugates |